Subtype
Thyroid Gland Carcinoma
CI-CAN-00006937THCAExplore in graph →
96 active trials8 approved drugs53 evidence items
- NCIt
- C4815
- DOID
- 3963
- Other
- 1 more code
Loading cancer entity…
Subtype
CI-CAN-00006937THCAExplore in graph →
Clinical trials
389 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (42)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00625846 | Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer | completed | Phase 2 | 152 | National Cancer Institute (NCI)NIH | 5 | Feb 26, 2020 | clinicaltrials |
| NCT02614495 | Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma | completed | Phase 2 | 66 | Hutchison Medipharma LimitedINDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT00880503 | Collection of Tissue Samples for Study of Multidrug Resistance | completed | — | 325 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT00582712 | An Initial Study of Lithium in Patients With Medullary Thyroid Cancer | terminated | Phase 2 | 5 | University of Wisconsin, MadisonOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT01013597 | Trial of LBH589 in Metastatic Thyroid Cancer | completed | Phase 2 | 13 | University of Wisconsin, MadisonOTHER | 1 | Nov 29, 2019 | clinicaltrials |
| NCT01974284 | Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma | terminated | N/A | 7 | Yale UniversityOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT00654238 | Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer | completed | Phase 2 | 59 | University of PennsylvaniaOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT02657369 | A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) | terminated | Phase 2 | 34 | Eisai Inc.INDUSTRY | 5 | Oct 15, 2019 | clinicaltrials |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | terminated | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT02768753 | Comparison Between the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA) for Robotic Thyroidectomy | completed | N/A | 60 | Jinan Military General HospitalOTHER | 1 | Sep 27, 2019 | clinicaltrials |
| NCT02289144 | Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT02586350 | Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) | completed | Phase 2 / Phase 3 | 91 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 21, 2019 | clinicaltrials |
| NCT03889769 | Evaluation of Accuracy of One-Step Nucleic Acid Amplification (OSNA) in Diagnosis of Lymph Node Metastases of Papillary Thyroid Carcinoma | unknown | — | 50 | University of CagliariOTHER | 1 | Mar 26, 2019 | clinicaltrials |
| NCT00104871 | Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 19, 2018 | clinicaltrials |
| NCT00085293 | Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2018 | clinicaltrials |
| NCT00923247 | A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) | terminated | Phase 1 / Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2018 | clinicaltrials |
| NCT03411187 | Study on the Application of Convenient Foot-control Exhaust Method in Endoscopic Thyroidectomy | unknown | N/A | 100 | Bo Wang,MDOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT03454477 | Comparison Between Robotic, Endoscopic and Traditional Open Surgery in Thyroidectomy | unknown | N/A | 90 | Fujian Medical UniversityOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT03639662 | Psychological Impact of a Sophrological Accompaniment During the Announcement of Thyroid Cancer | unknown | N/A | 232 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Aug 21, 2018 | clinicaltrials |
| NCT03636945 | Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma(TEPCMT) | unknown | N/A | 62 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT03623516 | Overdiagnosis of Thyroid Cancer in the Marne and Ardennes Departments of France From 1975 to 2014(OTCancer) | completed | — | 2,008 | CHU de ReimsOTHER | 1 | Aug 9, 2018 | clinicaltrials |
| NCT01502410 | Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 3 | Jun 26, 2018 | clinicaltrials |
| NCT02465424 | Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients(QaLM) | completed | — | 173 | Velindre NHS TrustOTHER_GOV | 1 | May 22, 2018 | clinicaltrials |
| NCT03510143 | Effect of Polyglycolic Acid Mesh (Neoveil) in Thyroid Cancer Surgery | unknown | N/A | 330 | Seoul National University HospitalOTHER | 1 | Apr 27, 2018 | clinicaltrials |
| NCT03500666 | Comparative Study of Robot BABA Approach and Chest Breast Approach for Lateral Neck Dissection | unknown | N/A | 10 | Fujian Medical UniversityOTHER | 1 | Apr 18, 2018 | clinicaltrials |
| NCT01424878 | Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients | completed | — | 150 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2018 | clinicaltrials |
| NCT01811212 | Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2018 | clinicaltrials |
| NCT00126568 | Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer | terminated | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Jan 19, 2018 | clinicaltrials |
| NCT03387943 | PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma | unknown | Phase 2 | 30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 3, 2018 | clinicaltrials |
| NCT03359668 | CT Detection of Metastatic Lymphadenopathy in Papillary Thyroid Cancer | completed | N/A | 47 | University Health Network, TorontoOTHER | 0 | Dec 2, 2017 | clinicaltrials |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Sep 28, 2017 | clinicaltrials |
| NCT03239769 | Compare the Aesthetic Effect of Different Thyroidectomies | completed | N/A | 120 | Peking University Cancer Hospital & InstituteOTHER | 0 | Aug 9, 2017 | clinicaltrials |
| NCT02114658 | Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients | completed | Phase 2 | 18 | BayerINDUSTRY | 1 | Aug 3, 2017 | clinicaltrials |
| NCT02561533 | Detection of BRAF Mutation on FNAB From Papillary Thyroid Carcinoma | completed | N/A | 53 | University of AarhusOTHER | 1 | Jul 14, 2017 | clinicaltrials |
| NCT01392222 | Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others | completed | — | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 21, 2017 | clinicaltrials |
| NCT02442661 | Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer | completed | — | 103 | University of Colorado, DenverOTHER | 1 | Jun 12, 2017 | clinicaltrials |
| NCT01927887 | Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study | completed | N/A | 12 | Massachusetts General HospitalOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT03167385 | Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT01539655 | Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib(Vandetanib) | completed | Phase 1 | 34 | SanofiINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT02109250 | CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice(CaprelsaReg) | completed | — | 10 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT00519896 | Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer | completed | Phase 2 | 35 | University of WashingtonOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT01865838 | A Study Into the Effect of Seprafilm in Open Total Thyroidectomy | terminated | N/A | 19 | National Cancer Centre, SingaporeOTHER | 1 | Apr 12, 2017 | clinicaltrials |
| NCT01240590 | A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) | completed | Phase 1 / Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2017 | clinicaltrials |
| NCT00729157 | Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01534897 | Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436 | completed | N/A | 10 | Massachusetts General HospitalOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT00118248 | Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00559949 | Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 2 | Jan 30, 2017 | clinicaltrials |
| NCT02952612 | Active Surveillance of Papillary Thyroid Microcarcinoma | unknown | — | 300 | Dong Jun LimOTHER | 1 | Nov 8, 2016 | clinicaltrials |
| NCT02323724 | APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS. | completed | — | 25 | Corporacion Parc TauliOTHER | 1 | Sep 22, 2016 | clinicaltrials |
| NCT01915485 | Radiolabeled Molecules for Medullary Thyroid Cancer | unknown | Phase 4 | 20 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Sep 7, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Feb 26, 2020source: clinicaltrials